Evidence-based Evaluation and Mechanism of Shenhuang Granules in the Treatment of Sepsis

Launched by THE FIRST AFFILIATED HOSPITAL OF ZHEJIANG CHINESE MEDICAL UNIVERSITY · Jul 16, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called Shenhuang Granules for patients with sepsis, a serious condition that occurs when the body's response to an infection leads to organ dysfunction. Sepsis is life-threatening and is a major cause of death worldwide, and unfortunately, there aren’t many effective drug treatments available. The researchers believe that Shenhuang Granules, which come from traditional Chinese medicine, might help improve patients' immune responses, potentially leading to better outcomes for those suffering from sepsis.

To participate in this trial, you need to be at least 18 years old and diagnosed with sepsis according to specific medical guidelines. However, there are some exclusions, such as having severe liver or kidney problems, being expected to die within 48 hours, or having had certain treatments recently. If you join the trial, you can expect to receive the Shenhuang Granules and be monitored closely by the medical team to see how well it works in improving your condition. This research aims to provide new insights into treating sepsis and may contribute to better care for patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥18 years old
• • Meet the diagnostic criteria of sepsis 3.0 guidelines
• • Sign informed consent.
• Exclusion Criteria:
• • Liver or kidney single SOFA score ≥3 points of liver and kidney dysfunction
• • Death is expected within 48 hours, or SOFA≥15 points, or APACHE II ≥30 points, or the patient refuses active treatment
• • Patients with allergic reactions to traditional Chinese medicine
• • Patients treated with chemotherapy or radiotherapy or high-dose immunosuppressants within the last 1 month
• • Participants in other clinical trials at the same time or within 30 days
• • Pregnant and lactating women
• • Patients with severe gastrointestinal bleeding, intestinal obstruction, or severe intraperitoneal pressure elevation (IAP≥20mmHg).